Michelle Ferreira, DO
Michelle Ferreira, DO
Michelle Ferreira, DO is a Board Certified Neurologist that practices in South Palm Beach / North Broward Counties area. She is Fellowship trained in Movement Disorders and subspecializes in Parkinson’s disease, Essential Tremors, Botulinum Toxins, Functional Neurological Disorders, and Gait Disorders. Dr. Ferreira received her medical degree from Nova Southeastern University. She completed her Neurology Residency at the University of Miami, and her Movement Disorders Fellowship at Cleveland Clinic Florida. She is a Clinical Professor of Neurology at the College of Osteopathic Medicine and an Adjunct Professor at the Dental College of Nova Southeastern University. Dr. Michelle Ferreira’s unique holistic approach, and genuine care for her patients, results in a more satisfying visit experience.
Dr. Michelle Ferreira evaluates and treats patients with Parkinson’s Disease, Essential Tremors, Lewy Body Dementia, Alzheimer’s Dementia, Neuropathies, Migraines, Strokes, Trigeminal Neuralgia, Fibromyalgia, Multiple Sclerosis, and Epilepsy.
Dr. Ferreira is a member of the American Academy of Neurology, Movement Disorders Society, American Medical Association, and Florida Medical Osteopathic Association.
Schedule a Telemedicine Appointment
(You must first call the office at (561) 962-1508 to schedule an appointment. Please do not click on the link and enter the waiting room unless you have a scheduled appointment).
Parkinson’s Disease, Essential Tremors, Gait Disorders, Migraines, Lewy Body Dementia, Alzheimer’s Dementia, Functional Movement Disorders, Fibromyalgia
American Board of Psychiatry and Neurology
Botulinum toxins for Neurological Disorders (Botox, Dysport, Myobloc, Xeomin)
Deep Brain Stimulation
Cannabis (Medical Marijuana) for the treatment of Neurological Disorders
Nerve Conduction Studies (NCS)
Small Fiber Biopsy
IVIG (Immunoglobulin Therapies)
Nova Southeastern University, Ft. Lauderdale, FL
Adult Neurology Resident
Jackson Memorial Hospital/University of Miami, Miami, FL Jul. 2008-June 2011
Movement Disorder Fellowship / Staff Neurologist Cleveland Clinic Florida, Weston, FL Jul 2011 – June 2012
American Medical Association (AMA) 2013-Present
American Academy of Neurology 2008-Present
Movement Disorder Society 2011-Present
Florida Society of Neurology 2009-Present
Florida Osteopathic Medical Association 2012-Present
Awards & Accolades
Clinical Preceptor for Medical Students at Nova Southeastern College of Osteopathic Medicine.
Lecturer for Internal Medicine Residents at Palmetto General Hospital, Miami.
Board Certification by the American Board of Psychiatry and Neurology Sept. 2012 – 2022 # 57489
Florida Medical License, Florida, OS 11301, active
Controlled Substance Registration Certificate, Active
NIH Stroke Scale Certification, American Heart Association, 2008-Present
Deep Brain Stimulation Programming, Medtronic Certification 2011
Research & Clinical Trials
Genzyme OBS13434-A Prospective, Multicenter, Observational, Post-Authorization Study To Evaluate The Long-Term Safety Profile Of Lemtrada Treatment In Patients With Relapsing Forms Of Multiple Sclerosis.
Avanir 15-AVP-786-301-A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy, Safety And Tolerability Of AVP-786 For The Treatment Of Agitation In Patient With Dementia Of The Alzheimer’s Type.
Luitpold 1VIT13037 – A double-blind, multi-center, randomized, placebo-controlled study to investigate the efficacy and safety of Injectafer (Ferric Carboxymaltose) in the treatment of Restless Legs Syndrome (RLS) Bayer Healthcare/Xcenda 17942 – Impact of the BETACONNECT auto-injector on BETASERON therapy adherence and patient satisfaction
Amgen 20150133 Evidera A-16821 – A prospective observational study to evaluate tolerability and outcomes of prophylactic therapies in Migraines BioDelivery BDSI BNX-401 – Prospective Evaluation of Treatment Satisfaction with Buprenorphine/Naloxone Buccal Film in Opioid-Dependent Subjects
Biogen POP 105MS401 – Plegridy Observational Program to assess the overall long-term clinical effectiveness of Plegridy in participants with relapsing forms of MS
Hoffman La-Roche VANILLA BP28420E – A multi-center, randomized, double-blind, 12-week parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of RO5285119 in individuals with Autism spectrum disorders (ASD)
Novartis EXPAND CBAF312A2304 – Evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis
Novartis PASSAGE FTY720D3403 – Safety Study in Patients with Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
PET STUDY DCA-2 – Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship between Scan Status and Cognitive Decline in Alzheimer’s Patients
UCB Bioscience SP0993 – Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older Novartis
PREFERMS CFTY720DUS09 –Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease-Modifying Therapy in Patients with Relapsing-Remitting Multiple Sclerosis
PET STUDY DCA-1 – Potential of Florbetapir F18 PET to Inform Clinical Diagnosis and Management of Alzheimer’s Patients with Progressive Cognitive Decline
Ipsen A-TL 52150-56 Anchor-DC – DYSPORT™ Clinical & Health Economics Outcomes Registry in Cervical Dystonia
Accepts New Patients
Read her Google Reviews
5350 W. Hillsboro Blvd., Suite 108
Coconut Creek, FL 33073
Phone: (561) 962-1508
Fax: (561) 962-1564
Monday – Friday:
8:30 a.m. – 5:00 p.m.
West Boca Medical Center
Michelle Ferreira, DO is a neurologist located in Coconut Creek, Florida. You can contact her office at (561) 962-1508.